For the year ending 2025-12-31, COLL had $155,546K increase in cash & cash equivalents over the period. $327,583K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Product revenues, net | 780,567 |
| Cost of product revenues (excluding intangible asset amortization) | 95,418 |
| Intangible asset amortization | 221,892 |
| Commercial expenses | 161,495 |
| Corporate expenses | 45,550 |
| Medical expenses | 29,754 |
| Technical operations expenses | 526 |
| Stock-based compensation expense | 41,906 |
| Other segment items | 4,390 |
| Interest expense | 82,312 |
| Interest income | 11,289 |
| Loss on extinguishment of debt | -15,994 |
| Provision for income taxes | 29,749 |
| Net income | 62,870 |
| Amortization expense | 221,892 |
| Depreciation expense | 4,182 |
| Deferred income taxes | -25,657 |
| Stock-based compensation expense | 41,906 |
| Non-cash lease expense (benefit) | 339 |
| Loss on extinguishment of debt | -15,994 |
| Non-cash interest expense for amortization of debt discount and issuance costs | 5,341 |
| Non-cash interest expense for deferred royalty obligation | 950 |
| Net amortization of premiums and discounts on investments | 1,072 |
| Non-cash change in fair value of contingent consideration | -1,182 |
| Accounts receivable | -17,204 |
| Inventory | 5,353 |
| Prepaid expenses and other assets | 7,968 |
| Accounts payable | 6,718 |
| Accrued liabilities | -9,495 |
| Accrued rebates, returns and discounts | 2,851 |
| Operating lease assets and liabilities | 25 |
| Deferred revenue | -222 |
| Net cash provided by operating activities | 329,323 |
| Acquisition of ironshore (net of cash acquired) | 0 |
| Purchases of property and equipment | 1,740 |
| Purchases of marketable securities | 126,968 |
| Maturities and sales of marketable securities | 65,176 |
| Net cash used in investing activities | -63,532 |
| Proceeds from issuances of common stock from employee stock purchase plans | 1,363 |
| Proceeds from the exercise of stock options | 4,280 |
| Payments made for employee stock tax withholdings | 12,846 |
| Repurchases of common stock | 25,104 |
| Repayment of term loans, including debt extinguishment costs | 635,558 |
| Proceeds from issuance of 2025 credit facility, net of debt discount and issuance costs | 565,175 |
| Payments made for deferred purchase price for acquisition | 7,555 |
| Proceeds from term note modification, net of fees paid to lender | 0 |
| Proceeds from issuances of 2029 convertible notes, net of issuance costs | 0 |
| Repurchase of 2026 convertible notes, including premium | 0 |
| Redemption of 2026 convertible notes, including premium and redemption costs | 0 |
| Repayment of assumed debt from ironshore acquisition | 0 |
| Net cash used in financing activities | -110,245 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 155,546 |
| Cash, cash equivalents and restricted cash at beginning of year | 96,612 |
| Cash, cash equivalents and restricted cash at end of year | 252,158 |
COLLEGIUM PHARMACEUTICAL, INC (COLL)
COLLEGIUM PHARMACEUTICAL, INC (COLL)